2024
TLR5-deficiency controls dendritic cell subset development in an autoimmune diabetes-susceptible model
Pearson J, Hu Y, Peng J, Wong F, Wen L. TLR5-deficiency controls dendritic cell subset development in an autoimmune diabetes-susceptible model. Frontiers In Immunology 2024, 15: 1333967. PMID: 38482010, PMCID: PMC10935730, DOI: 10.3389/fimmu.2024.1333967.Peer-Reviewed Original ResearchConceptsToll-like receptor 5Antigen-presenting cellsDendritic cellsType 1 diabetesTLR5-deficientDC developmentCytokine secretionCD4<sup>+</sup> T cell proliferationPathogenesis of type 1 diabetesT cell responsesEnhanced cytokine secretionT cell proliferationWild-type miceSusceptibility to obesitySusceptibility to T1DProinflammatory cytokine secretionGut microbiotaSpontaneous T1DNOD miceAutoimmune diabetesNon-obeseHuman T1DReceptor 5Autoimmune diseasesHyper-secretion
2023
Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor
Zhuang W, Zhang W, Xie L, Wang L, Li Y, Wang Z, Zhang A, Qiu H, Feng J, Zhang B, Hu Y. Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor. International Journal Of Molecular Sciences 2023, 24: 17631. PMID: 38139459, PMCID: PMC10743877, DOI: 10.3390/ijms242417631.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesSortilin 1Breast tumorsTumor antigen heterogeneityAdvanced breast tumorsSuperior safety profileAnti-tumor activityBreast tumor cell linesSafety profileADC targetBreast cancerCell cytotoxicityBystander killingTumor cell linesDrug resistanceAntigen heterogeneityTumorsPromising targetNew targetsTreatmentCell linesHER2Effective cytotoxicityTumor suppressionLysosomal traffickingGeneration of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
Zhuang W, Zhang W, Wang L, Xie L, Feng J, Zhang B, Hu Y. Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor. International Journal Of Molecular Sciences 2023, 24: 16056. PMID: 38003245, PMCID: PMC10671096, DOI: 10.3390/ijms242216056.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Low HER2 expressionHER2 expressionSortilin 1Antitumor efficacyEpidermal growth factor receptor 2MDA-MB-231 xenograft mouse modelTumor cellsGrowth factor receptor 2High HER2 expressionTreatment of patientsXenograft mouse modelFactor receptor 2Bispecific antibody-drug conjugatesAntibody-drug conjugatesTreatment of tumorsExpression tumorsMouse modelReceptor 2Bispecific antibody drugsToxic payloadsBispecific antibodiesTumorsNormal tissuesAntibody drugs